HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era

Background. The outcome of HIV-associated non-Hodgkin lymphoma (NHL) has improved substantially in the highly active antiretroviral therapy (HAART) era. However, HIV-Burkitt lymphoma (BL), which accounts for up to 20% of HIV-NHL, has poor outcome with standard chemotherapy. Patients and Methods. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigo, J. A., Hicks, L. K., Cheung, M. C., Song, K. W., Ezzat, H., Leger, C. S., Boro, J., Montaner, J. S. G., Harris, M., Leitch, H. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235428/
https://www.ncbi.nlm.nih.gov/pubmed/22190945
http://dx.doi.org/10.1155/2012/735392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235428/
https://www.ncbi.nlm.nih.gov/pubmed/22190945
http://dx.doi.org/10.1155/2012/735392

Ejemplares similares